Drugs / Sodium Fluoride F-18
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FLUORINE F-18 | — | 1972-02-24 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06914999 | Dec 2024 → Aug 2026 overdue | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oropharynx squamous cell carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02429804 | Apr 2015 → May 2017 | hormone-resistant prostate carcinoma, metastatic carcinoma in the bone, metastatic prostate carcinoma | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT05614518 | Mar 2021 → Jun 2022 | musculoskeletal system cancer | HTA Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04981509 Background | Jun 2022 → Dec 2027 expected | hereditary leiomyomatosis and renal cell cancer, papillary renal cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Fluoride F-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05614518 ↗ |
| Known as | Fluorine F 18 Sodium Fluoride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02429804 ↗ |
| Modality | Diagnostic / imaging agent | “positron emission tomography (PET)” NCT02429804 ↗ |
| Route | Intravenous | “Given IV” NCT02429804 ↗ |